🔗 Share this article

While America proceeds with unprecedented changes to its vaccination recommendations, an unexpected name appears in a surprising turn: Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccines throughout the pandemic and has concentrated on alleged deaths after Covid immunization in her brief time at the Food and Drug Administration.

Proposed Changes to Childhood Vaccine Program

Health officials planned to unveil major changes to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s national calendar, according to reports – a major change that would place the US out of step with much of the international standard with insufficient data for public health gain. The announcement has been postponed until the next year.

In place of the director of the vaccine center, Høeg is scheduled to present at the gathering. She was recently named acting director of the FDA’s CDER, the fifth appointee to head the office this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics centers as Høeg and Prasad solidify control at the FDA – and it signals a greater focus upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing certain childhood shot schedules in the US to become more like the Danish model, a nation with universal health coverage and a number of inhabitants about the size of Wisconsin’s.

So far comments, she has kept her attention on immunizations – usually the domain of Dr. Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Questions Over Qualifications

Høeg has little discernible experience in medication creation, regulation or administrative roles, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and the vaccine center since March.

“She doesn’t seem to have the necessary background” for running the CDER, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a major agency. She lacks background in pharmaceutical oversight.”

Previous commissioners of CBER would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she doesn’t have the type of experience that prior appointees who led CBER have had.”

This division has an immense portfolio at the agency, Woodcock emphasized.

“Many people just zeroes in on the novel medication approvals, but the generic drug division authorizes thousands of generic drugs. There is also a biosimilars division, OTC medication office and more, and all of those need to be managed,” Dr. Woodcock explained. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership component to the position, which oversees over 5,000 staff members. “It’s a enormous administrative position, if you do it right,” the former official added.

Agency Reaction and Contentious Programs

When asked about inquiries about Høeg’s fitness for the role and whether this assignment signifies greater collaboration among regulatory chiefs on immunizations, a press secretary said that the “questions are based on flawed premises”.

“Her experience aligns with the responsibilities of her role,” the representative said, citing the time Dr. Høeg spent counseling the agency head on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a contentious rapid medication authorization process that apparently concerned her preceding directors. “How are these therapies being chosen for this fast-track system? Who makes the decisions?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the regulatory body right now.”

In general, he remarked, “the FDA seems to be moving towards more relaxed oversight of all drugs, except for immunizations.”

Established Track Record on Vaccines

With immunizations, Høeg has a more established, if troubling, history, critics said. She authored a analysis using unconfirmed public submissions to estimate the rate of heart inflammation following Covid vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccines are riskier than they are.

Among her “wish list” for the new administration included changing regulations for recently developed shots and discontinuing “unnecessary” immunizations, she said after the election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of barring adolescent males from receiving Covid vaccines.

“She’s an thorough true believer who starts off with her preconceived notions and tailors the evidence to fit the evidence in a highly deceptive, untruthful way,” Howard argued.

Taking Control and a “Push for Payback”

Høeg became part of other skeptics, {like|